Inclusion Body Myositis.
Journal
Continuum (Minneapolis, Minn.)
ISSN: 1538-6899
Titre abrégé: Continuum (Minneap Minn)
Pays: United States
ID NLM: 9509333
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
20
12
2022
pubmed:
21
12
2022
medline:
23
12
2022
Statut:
ppublish
Résumé
This article highlights the clinical and diagnostic features of inclusion body myositis (IBM) and provides recent insights into the pathomechanisms and therapeutic strategies of the disease. IBM is an often-misdiagnosed myopathy subtype. Due to the insidious onset and slow progression of muscle weakness, it can often be dismissed as a sign of aging as it commonly presents in older adults. While challenging to recognize upon initial clinical evaluation, the recent recognition of specialized stains highlighting features seen on muscle pathology, the use of diagnostic tools such as the anti-cytosolic 5'-nucleotidase 1A antibody biomarker, and the ability of muscle imaging to detect patterns of preferential muscle involvement seen in IBM has allowed for earlier diagnosis of the disease than was previously possible. While the pathogenesis of IBM has historically been poorly understood, several ongoing studies point toward mechanisms of autophagy and highly differentiated cytotoxic T cells that are postulated to be pathogenic in IBM. Overall advancements in our understanding of IBM have resulted in improvements in the management of the disease and are the foundation of several strategies for current and upcoming novel therapeutic drug trials in IBM.
Identifiants
pubmed: 36537974
doi: 10.1212/CON.0000000000001204
pii: 00132979-202212000-00008
doi:
Substances chimiques
Autoantibodies
0
5'-Nucleotidase
EC 3.1.3.5
Biomarkers
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1663-1677Informations de copyright
Copyright © 2022 American Academy of Neurology.
Références
Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology 2021;96(21):e2653–e2661. doi:10.1212/WNL.0000000000012004
doi: 10.1212/WNL.0000000000012004
Molberg Ø, Dobloug C. Epidemiology of sporadic inclusion body myositis. Curr Opin Rheumatol 2016;28(6):657–660. doi:10.1097/BOR.0000000000000327
doi: 10.1097/BOR.0000000000000327
Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 2019;15(5):257–272. doi:10.1038/s41584-019-0186-x
doi: 10.1038/s41584-019-0186-x
Cox FM, Verschuuren JJ, Verbist BM, et al. Detecting dysphagia in inclusion body myositis. J Neurol 2009;256(12):2009–2013. doi:10.1007/s00415-009-5229-9
doi: 10.1007/s00415-009-5229-9
Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73(3):408–418. doi:10.1002/ana.23840
doi: 10.1002/ana.23840
Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73(3):397–407. doi:10.1002/ana.23822
doi: 10.1002/ana.23822
Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016;75(4):696–701. doi:10.1136/annrheumdis-2014-206691
doi: 10.1136/annrheumdis-2014-206691
Greenberg SA. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014;50(4):488–492. doi:10.1002/mus.24199
doi: 10.1002/mus.24199
Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res (Hoboken) 2016;68(1):66–71. doi:10.1002/acr.22600
doi: 10.1002/acr.22600
Rietveld A, van den Hoogen LL, Bizzaro N, et al. Autoantibodies to cytosolic 5'-nucleotidase 1A in primary sjögren's syndrome and systemic lupus erythematosus. Front Immunol 2018;9:1200. doi:10.3389/fimmu.2018.01200
doi: 10.3389/fimmu.2018.01200
Liewluck T. Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases. Neurology 2017;89(19):2017–2018. doi:10.1212/WNL.0000000000004610
doi: 10.1212/WNL.0000000000004610
Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry 2016;87(4):373–378. doi:10.1136/jnnp-2014-310008
doi: 10.1136/jnnp-2014-310008
Lilleker JB, Rietveld A, Pye SR, et al. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis 2017;76(5):862–868. doi:10.1136/annrheumdis-2016-210282
doi: 10.1136/annrheumdis-2016-210282
Ikenaga C, Findlay AR, Goyal NA, et al. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies. Ann Clin Transl Neurol 2021;8(3):571–578. doi:10.1002/acn3.51294
doi: 10.1002/acn3.51294
Malartre S, Bachasson D, Mercy G, et al. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol 2021;31(3):e12954. doi:10.1111/bpa.12954
doi: 10.1111/bpa.12954
Van De Vlekkert J, Maas M, Hoogendijk JE, et al. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve 2015;51(2):253–258. doi:10.1002/mus.24307
doi: 10.1002/mus.24307
Cox FM, Reijnierse M, van Rijswijk CSP, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011;50(6):1153–1161. doi:10.1093/rheumatology/ker001
doi: 10.1093/rheumatology/ker001
Tasca G, Monforte M, De Fino C, et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 2015;52(6):956–962. doi:10.1002/mus.24661
doi: 10.1002/mus.24661
Morrow JM, Sinclair CDJ, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016;15(1):65–77. doi:10.1016/S1474-4422(15)00242-2
doi: 10.1016/S1474-4422(15)00242-2
Leeuwenberg KE, van Alfen N, Christopher-Stine L, et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve 2020;61(6):783–788. doi:10.1002/mus.26875
doi: 10.1002/mus.26875
Guimaraes JB, Cavalcante WCP, Cruz IAN, et al. Musculoskeletal ultrasound in inclusion body myositis: a comparative study with magnetic resonance imaging. Ultrasound Med Biol 2021;47(8):2186–2192. doi:10.1016/j.ultrasmedbio.2021.04.019
doi: 10.1016/j.ultrasmedbio.2021.04.019
Ikenaga C, Kubota A, Kadoya M, et al. Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology 2017;89(10):1060–1068. doi:10.1212/WNL.0000000000004333
doi: 10.1212/WNL.0000000000004333
van de Vlekkert J, Hoogendijk JE, de Visser M. Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled. Neuromuscul Disord 2015;25(6):451–456. doi:10.1016/j.nmd.2015.02.014
doi: 10.1016/j.nmd.2015.02.014
Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998;113(3):407–414. doi:10.1046/j.1365-2249.1998.00664.x
doi: 10.1046/j.1365-2249.1998.00664.x
Rodríguez Cruz PM, Luo Y-B, Miller J, et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 2014;24(12):1025–1035. doi:10.1016/j.nmd.2014.06.436
doi: 10.1016/j.nmd.2014.06.436
Uruha A, Goebel H-H, Stenzel W. Updates on the immunopathology in idiopathic inflammatory myopathies. Curr Rheumatol Rep 2021;23(7):56. doi:10.1007/s11926-021-01017-7
doi: 10.1007/s11926-021-01017-7
Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009;118(3):407–413. doi:10.1007/s00401-009-0564-6
doi: 10.1007/s00401-009-0564-6
Nakano S, Oki M, Kusaka H. The role of p62/SQSTM1 in sporadic inclusion body myositis. Neuromuscul Disord 2017;27(4):363–369. doi:10.1016/j.nmd.2016.12.009
doi: 10.1016/j.nmd.2016.12.009
Hiniker A, Daniels BH, Lee HS, Margeta M. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 2013;1:29. doi:10.1186/2051-5960-1-29
doi: 10.1186/2051-5960-1-29
Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 2014;83(5):426–433. doi:10.1212/WNL.0000000000000642
doi: 10.1212/WNL.0000000000000642
Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands. Neuromuscul Disord 2013;23(12):1044–1055. doi:10.1016/j.nmd.2013.08.007
doi: 10.1016/j.nmd.2013.08.007
Schmidt K, Schmidt J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr Opin Rheumatol 2017;29(6):632–638. doi:10.1097/BOR.0000000000000436
doi: 10.1097/BOR.0000000000000436
Weihl CC, Mammen AL. Sporadic inclusion body myositis—a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol 2017;43(1):82–91. doi:10.1111/nan.12384
doi: 10.1111/nan.12384
Vittonatto E, Boschi S, Chiadò-Piat L, et al. Differential diagnosis of vacuolar muscle biopsies: use of p62, LC3 and LAMP2 immunohistochemistry. Acta Myol 2017;36(4):191–198.
Cortese A, Plagnol V, Brady S, et al. Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy. Neurobiol Aging 2014;35(6):1491–1498. doi:10.1016/j.neurobiolaging.2013.12.029
doi: 10.1016/j.neurobiolaging.2013.12.029
Dimitri D, Benveniste O, Dubourg O, et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 2006;129(Pt 4):986–995. doi:10.1093/brain/awl020
doi: 10.1093/brain/awl020
Greenberg SA, Pinkus JL, Amato AA, et al. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain 2016;139(Pt 5):1348–1360. doi:10.1093/brain/aww024
doi: 10.1093/brain/aww024
Greenberg SA, Pinkus JL, Kong SW, et al. Highly differentiated cytotoxic T cells in inclusion body myositis. Brain 2019;142(9):2590–2604. doi:10.1093/brain/awz207
doi: 10.1093/brain/awz207
Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 2017;88(15):1454–1460. doi:10.1212/WNL.0000000000003821
doi: 10.1212/WNL.0000000000003821
Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol 2008;67(1):41–49. doi:10.1097/nen.0b013e31815f38b7
doi: 10.1097/nen.0b013e31815f38b7
Uruha A, Noguchi S, Hayashi YK, et al. Hepatitis C virus infection in inclusion body myositis: a case-control study. Neurology 2016;86(3):211–217. doi:10.1212/WNL.0000000000002291
doi: 10.1212/WNL.0000000000002291
Dalakas MC, Schmidt J. Viruses in IBM: hit-and-run, hide and persist, or irrelevant?Neurology 2016;86(3):204–205. doi:10.1212/WNL.0000000000002295
doi: 10.1212/WNL.0000000000002295
Rothwell S, Cooper RG, Lundberg IE, et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol 2017;69(5):1090–1099. doi:10.1002/art.40045
doi: 10.1002/art.40045
Weihl CC, Baloh RH, Lee Y, et al. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord 2015;25(4):289–296. doi:10.1016/j.nmd.2014.12.009
doi: 10.1016/j.nmd.2014.12.009
Güttsches A-K, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol 2017;81(2):227–239. doi:10.1002/ana.24847
doi: 10.1002/ana.24847
Gang Q, Bettencourt C, Machado PM, et al. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging 2015;36(4):1766.e1–1766.e3. doi:10.1016/j.neurobiolaging.2014.12.039
doi: 10.1016/j.neurobiolaging.2014.12.039
Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011;134(Pt 11):3167–3175. doi:10.1093/brain/awr217
doi: 10.1093/brain/awr217
Talotta R, Porrello I, Restuccia R, Magaudda L. Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review. Clin Rheumatol 2022;41(3):593–615. doi:10.1007/s10067-021-05954-7
doi: 10.1007/s10067-021-05954-7
Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 2019;18(9):834–844. doi:10.1016/S1474-4422(19)30200-5
doi: 10.1016/S1474-4422(19)30200-5
Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med 2016;8(331):331ra41. doi:10.1126/scitranslmed.aad4583
doi: 10.1126/scitranslmed.aad4583
Machado M, Barohn R, McDermott M, et al. A randomized, double-blind, placebo-controlled study of arimoclomol in patients with inclusion body myositis. Neurol 2022;98(18 Supplement):S23.010.
Benveniste O, Hogrel JY, Belin L, et al. Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatol 2021;3:40–48. doi:10.1016/S2665-9913(20)30280-0
doi: 10.1016/S2665-9913(20)30280-0